Advanced mesoporous silica nanocarriers in cancer theranostics and gene editing applications

J Control Release. 2021 Sep 10:337:193-211. doi: 10.1016/j.jconrel.2021.07.029. Epub 2021 Jul 20.

Abstract

Targeted nanomaterials for cancer theranostics have been the subject of an expanding volume of research studies in recent years. Mesoporous silica nanoparticles (MSNs) are particularly attractive for such applications due to possibilities to synthesize nanoparticles (NPs) of different morphologies, pore diameters and pore arrangements, large surface areas and various options for surface functionalization. Functionalization of MSNs with different organic and inorganic molecules, polymers, surface-attachment of other NPs, loading and entrapping cargo molecules with on-desire release capabilities, lead to seemingly endless prospects for designing advanced nanoconstructs exerting multiple functions, such as simultaneous cancer-targeting, imaging and therapy. Describing composition and multifunctional capabilities of these advanced nanoassemblies for targeted therapy (passive, ligand-functionalized MSNs, stimuli-responsive therapy), including one or more modalities for imaging of tumors, is the subject of this review article, along with an overview of developments within a novel and attractive research trend, comprising the use of MSNs for CRISPR/Cas9 systems delivery and gene editing in cancer. Such advanced nanconstructs exhibit high potential for applications in image-guided therapies and the development of personalized cancer treatment.

Keywords: Cancer imaging; Gene editing; Mesoporous silica nanoparticles (MSNs); Nanotheranostics; Targeted cancer therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Drug Carriers / therapeutic use
  • Drug Delivery Systems
  • Gene Editing
  • Humans
  • Nanoparticles*
  • Neoplasms* / drug therapy
  • Porosity
  • Precision Medicine
  • Silicon Dioxide / therapeutic use

Substances

  • Drug Carriers
  • Silicon Dioxide